Valuation: Virbac

Market Cap 278.56Cr 322.37Cr 262.04Cr 238.06Cr 447.13Cr 31TCr 454.81Cr 3.07TCr 1.2TCr 15TCr 1.21TCr 1.18TCr 51TCr P/E 2026 *
16.3x
P/E 2027 * 14.8x
Enterprise Value 291.24Cr 337.04Cr 273.96Cr 248.89Cr 467.47Cr 32TCr 475.51Cr 3.21TCr 1.25TCr 16TCr 1.26TCr 1.24TCr 54TCr EV / Sales 2026 *
1.88x
EV / Sales 2027 * 1.74x
Free-Float
49.03%
Yield 2026 *
0.52%
Yield 2027 * 0.61%
1 day-6.07%
1 month-6.07%
3 months-6.07%
6 months-12.16%
Current year-12.16%
1 month 382.75
Extreme 382.75
413.75
Current year 382.75
Extreme 382.75
413.75
1 year 382.75
Extreme 382.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-6.07%-.--% - - 322.52Cr
-2.70%+1.56%-52.12%-60.99% 3.05TCr
+5.15%+7.01%+31.79%+101.10% 1.18TCr
-0.48%-2.25%-20.12%+2.86% 377.18Cr
+0.30%-3.62%+0.45%+18.54% 322.52Cr
-0.81%-2.38%+51.51%+37.78% 218.63Cr
-0.28%+0.71%+13.74%+21.48% 196.74Cr
+0.88%+0.20%+12.03%+129.22% 139.38Cr
-2.18%+5.77%-15.50%+6.35% 129.6Cr
-0.90%+0.30%-12.73%-43.47% 100Cr
Average -0.71%+0.36%+1.01%+23.65% 635.05Cr
Weighted average by Cap. -0.77%+1.85%-20.37%-5.66%

Financials

2026 *2027 *
Net sales 155.09Cr 179.48Cr 145.89Cr 132.54Cr 248.94Cr 17TCr 253.22Cr 1.71TCr 667.94Cr 8.59TCr 673.21Cr 658.68Cr 29TCr 164.73Cr 190.64Cr 154.96Cr 140.78Cr 264.41Cr 18TCr 268.96Cr 1.81TCr 709.44Cr 9.12TCr 715.05Cr 699.61Cr 30TCr
Net income 17Cr 20Cr 16Cr 15Cr 27Cr 1.89TCr 28Cr 188.45Cr 74Cr 947.78Cr 74Cr 73Cr 3.15TCr 19Cr 22Cr 18Cr 16Cr 30Cr 2.09TCr 31Cr 208.75Cr 82Cr 1.05TCr 82Cr 81Cr 3.49TCr
Net Debt 13Cr 15Cr 12Cr 11Cr 20Cr 1.4TCr 21Cr 139.59Cr 55Cr 702.03Cr 55Cr 54Cr 2.34TCr 7.52Cr 8.7Cr 7.07Cr 6.42Cr 12Cr 829.49Cr 12Cr 83Cr 32Cr 416.29Cr 33Cr 32Cr 1.38TCr
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
332.50EUR
Average target price
411.88EUR
Spread / Average Target
+23.87%

Quarterly revenue - Rate of surprise